Occurrence of human papillomavirus (HPV) type replacement by sexual risk-taking behaviour group: Post-hoc analysis of a community randomized clinical trial up to nine years after vaccination (IV).
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Gray, PenelopeLuostarinen, Tapio
Vänskä, Simopekka
Eriksson, Tiina
Lagheden, Camilla
Man, Irene
Palmroth, Johanna
Pimenoff, Ville N
Söderlund-Strand, Anna
Dillner, Joakim
Lehtinen, Matti
Type
ArticleLanguage
en
Metadata
Show full item recordTitle
Occurrence of human papillomavirus (HPV) type replacement by sexual risk-taking behaviour group: Post-hoc analysis of a community randomized clinical trial up to nine years after vaccination (IV).Published in
Int J Cancer 2019; 145(3):785-96PMID
30719706ae974a485f413a2113503eed53cd6c53
10.1002/ijc.32189
Scopus Count
Collections
Related articles
- Evaluation of HPV type-replacement in unvaccinated and vaccinated adolescent females-Post-hoc analysis of a community-randomized clinical trial (II).
- Authors: Gray P, Palmroth J, Luostarinen T, Apter D, Dubin G, Garnett G, Eriksson T, Natunen K, Merikukka M, Pimenoff V, Söderlund-Strand A, Vänskä S, Paavonen J, Pukkala E, Dillner J, Lehtinen M
- Issue date: 2018 Jun 15
- Characteristics of a cluster-randomized phase IV human papillomavirus vaccination effectiveness trial.
- Authors: Lehtinen M, Apter D, Baussano I, Eriksson T, Natunen K, Paavonen J, Vänskä S, Bi D, David MP, Datta S, Struyf F, Jenkins D, Pukkala E, Garnett G, Dubin G
- Issue date: 2015 Mar 3
- Impact of gender-neutral or girls-only vaccination against human papillomavirus-Results of a community-randomized clinical trial (I).
- Authors: Lehtinen M, Söderlund-Strand A, Vänskä S, Luostarinen T, Eriksson T, Natunen K, Apter D, Baussano I, Harjula K, Hokkanen M, Kuortti M, Palmroth J, Petäjä T, Pukkala E, Rekonen S, Siitari-Mattila M, Surcel HM, Tuomivaara L, Paavonen J, Dillner J, Dubin G, Garnett G
- Issue date: 2018 Mar 1
- Gender-neutral vaccination provides improved control of human papillomavirus types 18/31/33/35 through herd immunity: Results of a community randomized trial (III).
- Authors: Lehtinen M, Luostarinen T, Vänskä S, Söderlund-Strand A, Eriksson T, Natunen K, Apter D, Baussano I, Harjula K, Hokkanen M, Kuortti M, Palmroth J, Petäjä T, Pukkala E, Rekonen S, Siitari-Mattila M, Surcel HM, Tuomivaara L, Paavonen J, Nieminen P, Dillner J, Dubin G, Garnett G
- Issue date: 2018 Nov 1
- Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of <i>three cohorts from randomized trials</i>.
- Authors: Lehtinen M, Lagheden C, Luostarinen T, Eriksson T, Apter D, Harjula K, Kuortti M, Natunen K, Palmroth J, Petäjä T, Pukkala E, Siitari-Mattila M, Struyf F, Nieminen P, Paavonen J, Dubin G, Dillner J
- Issue date: 2017 Aug 18